Hyloris Pharmaceuticals (XBRU:HYL) 3-Year EBITDA Growth Rate : -28.10% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals 3-Year EBITDA Growth Rate?

Hyloris Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was €-0.31.

During the past 3 years, the average EBITDA Per Share Growth Rate was -28.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -29.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hyloris Pharmaceuticals was -18.80% per year. The lowest was -63.00% per year. And the median was -23.95% per year.

Competitive Comparison of Hyloris Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Hyloris Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Hyloris Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hyloris Pharmaceuticals (XBRU:HYL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hyloris Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.